Allos Therapeutics, Inc. To Present At The 2006 Biotechnology Industry Organization (BIO) CEO & Investor Conference

WESTMINSTER, Colo., Feb. 1 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced that the Company will participate in the 2006 BIO CEO & Investor Conference, to be held February 14th - 15th in New York City. Michael E. Hart, the Company's President and Chief Executive Officer, will give a 25-minute corporate overview on Wednesday, February 15th at 10:30 AM ET.

The presentation will be webcast live and may be accessed by visiting the Allos website at A replay of the webcast will also be available on the Company's website until Wednesday, March 1, 2006.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed to sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation therapy. EFAPROXYN is currently being evaluated as an adjunct to whole brain radiation therapy in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer. The Company's other product candidates are: PDX (pralatrexate), a small molecule chemotherapeutic agent (DHFR inhibitor) currently under investigation as both a single agent and in combination therapy regimens in patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule chemotherapeutic agent bioactivated by the enzyme DT-diaphorase currently under evaluation in patients with advanced solid tumors. For more information, please visit the Company's web site at:

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties, including those to be discussed in the presentation and others that can be found in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2004 and in the Company's periodic reports on Form 10-Q and Form 8-K. The Company does not undertake any obligation to update any forward-looking statements contained in the anticipated presentation as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.

Allos Therapeutics, Inc.

CONTACT: Jennifer Neiman, Manager, Corporate Communications of AllosTherapeutics, Inc., +1-720-540-5227,

Back to news